Treatment course for each MLBL patient treated in the FAB/LMB 96 study. All MLBL patients received Group B therapy initially. After the COP reduction phase, patients with a CR or intermediate response (defined as a 20%-99% reduction in the product of the 2 largest diameters of evaluable lesions) continued on Group B therapy. At the third evaluation, a CR included residual masses as long as adequate biopsy demonstrated no viable tumor. Patients with residual viable tumors (persistent disease) were switched to Group C therapy beginning with CYVE1 consolidation. Nine patients in CR continued onto Group C M1-M4 therapy, 1 patient from Group B and 8 patients from Group C. Patients with disease progression (> 25% increase in the product of 2 largest diameters) were taken off study. Disease status at last follow-up for all patients completing therapy is included.